Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Abstract Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone. Case presentation We report the case of a 49 y...
Main Authors: | Santino Minichillo, Ilaria Gallelli, Elena Barbieri, Marta Cubelli, Daniela Rubino, Sara Quercia, Massimo Dall’Olio, Claudio Rapezzi, Claudio Zamagni |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3712-8 |
Similar Items
-
Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer
by: Iljovska Marina, et al.
Published: (2023-01-01) -
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023-02-01) -
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
by: Holden Eaton, et al.
Published: (2023-04-01) -
Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
by: Mohamed Aboulfotouh Mourad, et al.
Published: (2023-12-01)